Total Payments
$147,374
2021 Payments
$147,364
Companies
2
Transactions
5
Medicare Patients
2,434
Medicare Billing
$238,320
Payment Breakdown by Category
Research$147,364 (100.0%)
Food & Beverage$10.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $147,364 | 4 | 100.0% |
| Food and Beverage | $10.50 | 1 | 0.0% |
Payments by Type
Research
$147,364
4 transactions
General
$10.50
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $147,364 | 4 | $0 (2021) |
| ARBOR PHARMACEUTICALS, INC. | $10.50 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $147,364 | 4 | Eli Lilly and Company ($147,364) |
| 2018 | $10.50 | 1 | ARBOR PHARMACEUTICALS, INC. ($10.50) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/28/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $25,450.00 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 06/28/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $20,450.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | ||||||
| 04/27/2021 | Eli Lilly and Company | — | — | In-kind items and services | $2,083.88 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | ||||||
| 03/31/2021 | Eli Lilly and Company | — | — | In-kind items and services | $99,380.03 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 08/10/2018 | ARBOR PHARMACEUTICALS, INC. | Otovel (Drug) | Food and Beverage | In-kind items and services | $10.50 | General |
| Category: Pediatrics/Neonatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $124,830 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $22,534 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 481 | 691 | $126,375 | $49,234 |
| 2022 | 12 | 835 | 1,112 | $195,712 | $84,976 |
| 2021 | 12 | 890 | 1,103 | $188,095 | $80,952 |
| 2020 | 3 | 228 | 248 | $64,234 | $23,158 |
Total Patients
2,434
Total Services
3,154
Medicare Billing
$238,320
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2023 | 94 | 121 | $30,250 | $16,913 | 55.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 112 | 217 | $39,221 | $14,248 | 36.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 37 | 78 | $20,436 | $7,427 | 36.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 90 | 90 | $23,940 | $6,891 | 28.8% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 24 | 25 | $2,500 | $1,257 | 50.3% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2023 | 20 | 26 | $2,600 | $1,054 | 40.6% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 33 | 34 | $1,700 | $550.80 | 32.4% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 25 | 28 | $2,128 | $462.42 | 21.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 16 | 33 | $1,650 | $344.64 | 20.9% |
| 81003 | Automated urinalysis test | Office | 2023 | 30 | 39 | $1,950 | $85.80 | 4.4% |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2022 | 120 | 140 | $35,075 | $19,697 | 56.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 142 | 227 | $41,087 | $18,585 | 45.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 182 | 182 | $48,412 | $17,986 | 37.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 99 | 149 | $39,038 | $15,514 | 39.7% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 88 | 123 | $9,205 | $6,193 | 67.3% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2022 | 93 | 109 | $16,350 | $5,563 | 34.0% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 15 | 16 | $1,350 | $650.46 | 48.2% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2022 | 25 | 25 | $1,210 | $406.63 | 33.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 22 | 28 | $1,265 | $288.19 | 22.8% |
| 81003 | Automated urinalysis test | Office | 2022 | 26 | 33 | $1,590 | $73.14 | 4.6% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2022 | 11 | 37 | $635.00 | $16.09 | 2.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 12 | 43 | $495.00 | $3.69 | 0.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 303 | 306 | $80,898 | $30,345 | 37.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 106 | 201 | $52,014 | $22,428 | 43.1% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 182 | 228 | $13,775 | $11,699 | 84.9% |
About Dr. Tewodros Teketel, M.D
Dr. Tewodros Teketel, M.D is a General Practice healthcare provider based in Katy, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/24/2013. The National Provider Identifier (NPI) number assigned to this provider is 1386070159.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tewodros Teketel, M.D has received a total of $147,374 in payments from pharmaceutical and medical device companies, with $147,364 received in 2021. These payments were reported across 5 transactions from 2 companies. The most common payment nature is "" ($147,364).
As a Medicare-enrolled provider, Teketel has provided services to 2,434 Medicare beneficiaries, totaling 3,154 services with total Medicare billing of $238,320. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty General Practice
- Other Specialties Internal Medicine, Internal Medicine
- Location Katy, TX
- Active Since 09/24/2013
- Last Updated 10/31/2025
- Taxonomy Code 208D00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1386070159
Products in Payments
- Otovel (Drug) $10.50
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in Katy
Laura Lukin, D.d.s, D.D.S
General Practice — Payments: $12,121
General Practice $12,121
Dr. Langley Ho, Dds, DDS
General Practice — Payments: $10,506
General Practice $10,506
Dr. Minhchau Nguyen, Dds, DDS
General Practice — Payments: $6,222
General Practice $6,222
Christopher Kimmel, Dds, DDS
General Practice — Payments: $3,981
General Practice $3,981
Dr. Jason Lee, D.d.s, D.D.S
General Practice — Payments: $3,903
General Practice $3,903
Dr. Colin Lathrop, Dds, DDS
General Practice — Payments: $3,534
General Practice $3,534